These mutations occur in more than 90% of pancreatic cancer cases and drastically reduce response to immunotherapy.
A new study in
Nature Communications takes an initial step toward better understanding how KRAS drives immune evasion and demonstrates a lowering of the KRAS activity resulting in a more favorable immune environment to fight cancer.
Previous strategies to block the KRAS oncogene therapeutically have focused on counteracting its growth-promoting role in cancer.
“Instead, our study shows that oncogenic KRAS plays a profound immunosuppressive role in cancer maintenance, and that treatment of cancer will be improved by simultaneously inhibiting KRAS and activating immune pathways suppressed by the cancer,” says Oleksi Petrenko, research assistant professor in the department of microbiology and immunology in the Renaissance School of Medicine at Stony Brook University.
Photo by Samuel Corum/Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Biden is starting his administration s efforts to fast-track cancer-treatment research.
He held a meeting Wednesday with a bipartisan group of lawmakers to discuss his plans.
Biden s nominee to lead White House science policy, Eric Lander, is expected to lead the effort.
President Joe Biden has jump-started efforts to bolster research on cancer treatments and cures, picking up from where he left off as Barack Obama s vice president.
The issue has been a priority for Biden, whose son Beau Biden died of brain cancer in 2015.
E-Mail
Women of minority races and ethnicities and with less education and income have had relatively lower access to 3D mammography, a technology that can improve breast cancer detection and decrease false alarms, according to research published today. This study was about whether adoption of this technology is equitable. We re showing that it has not been, even though it has been FDA-approved for a decade now, said Dr. Christoph Lee, professor of radiology at the University of Washington School of Medicine. Black and Hispanic women, and less-educated and lower-income women have not been able to obtain 3D mammography as easily as white, well-educated, and higher-income women.
Date Time
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine.
The NEOSTAR trial tested combined neoadjuvant therapy of nivolumab plus ipilimumab, as well as neoadjuvant nivolumab monotherapy in patients with operable NSCLC. The trial met its prespecified primary endpoint efficacy threshold in the combination arm, with eight of 21 treated patients (38%) achieving major pathological response, defined as ≤10% viable tumor at surgery. MPR has been show
This award will be administered by the U.S. Department of Health and Human Services (HHS).
âOn this World Cancer Day, we extend love to those who have lost someone to this devastating disease, we cheer those who are beating the odds, and we stand with all those among us who are still battling each and every day to be cancer-free,â Tonko said. âOur extraordinary achievement in COVID vaccine development is an important reminder that investments in science and public health research can and do spread hope and save lives. We owe more than gratitude to the doctors and scientists who are researching new treatments and finding cures. We owe them our vocal support and our commitment that we will continue to invest in their powerful work. I applaud the local scientists and researchers who are working on making these remarkable new discoveries and are helping improve cancer treatments for patients here and around the world.